Nintedanib Clinical Trials
6 recruitingDrug
Phase 22Phase 32Phase 41
Showing 1–6 of 6 trials
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
Systemic Sclerosis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company92 enrolled55 locationsNCT07335562
Recruiting
Phase 3
Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease
Interstitial Lung DiseaseSystemic Sclerosis
National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland86 enrolled1 locationNCT06297096
Recruiting
Phase 2
Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients
Telangiectasia, Hereditary Hemorrhagic
Dr. Romain Lazor48 enrolled3 locationsNCT04976036
Recruiting
Phase 2
Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation
Bronchiolitis Obliterans Syndrome (BOS)Bronchiolitis Obliterans (BO)
University Hospital, Basel, Switzerland20 enrolled3 locationsNCT03805477
Recruiting
Phase 4
RCT of Nintedanib in Fibrotic Sarcoidosis
Sarcoidosis, Pulmonary
Post Graduate Institute of Medical Education and Research, Chandigarh120 enrolled1 locationNCT06479603
Recruiting
Nintedanib for the Prevention of Radiation Pneumonia in Unresectable NSCLC
NSCLCRadiation PneumonitisNintedanib
Second Hospital of Shanxi Medical University40 enrolled7 locationsNCT06570317